Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours

(2009) Nobuyuki Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo

(2009) A. Oke et al.   CANCER RESEARCH

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

(2009) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

(2009) William L. Dahut et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors

(2008) S. A. Veltkamp et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

(2008) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors

(2008) Brigitte C. Widemann et al.   JOURNAL OF CLINICAL ONCOLOGY